Abstract:Background: The ability to predict Alzheimers disease (AD) before diagnosis is a topic of intense research. Early diagnosis would aid in improving treatment and intervention options, however, there are no current methods that can accurately predict AD years in advance. This study examines a novel machine learning approach that integrates the combined effects of vascular (white matter hyperintensities, WMHs), and structural brain changes (gray matter, GM) with clinical factors (cognitive status) to predict post-mortem neuropathological outcomes. Methods: Healthy older adults, participants with mild cognitive impairment, and AD from the Alzheimer's Disease Neuroimaging Initiative dataset with both post-mortem neuropathology data and antemortem MRI and clinical data were included. Longitudinal data were analyzed across three intervals before death (post-mortem data): 0-4 years, 4-8 years, and 8-14 years. Additionally, cross-sectional data at the last visit or interval (within four years, 0-4 years) before death were also examined. Machine learning models including gradient boosting, bagging, support vector regression, and linear regression were implemented. These models were applied towards feature selection of the top seven MRI, clinical, and demographic data to identify the best performing set of variables that could predict postmortem neuropathology outcomes (i.e., neurofibrillary tangles, neuritic plaques, diffuse plaques, senile/amyloid plaques, and amyloid angiopathy). Results: A total of 94 participants (55-90 years of age) were included in the study. At last visit, the best-performing model included total and temporal lobe WMHs and achieved r=0.87(RMSE=0.62) during cross-validation for neuritic plaques. For longitudinal assessments across different intervals, the best-performing model included regional GM (i.e., hippocampus, amygdala, caudate) and frontal lobe WMH and achieved r=0.93(RMSE=0.59) during cross-validation for neurofibrillary tangles. For MRI and clinical predictors and clinical-only predictors, t-tests demonstrated significant differences at all intervals before death (t[-13.60-7.90], p-values<0.001). Overall, post-mortem neuropathology outcome were predicted up to 14 years before death with high accuracies (~90%). Conclusions: Prediction accuracy was higher for post-mortem neuropathology outcomes that included MRI (WMHs, GM) and clinical features compared to clinical-only features. These findings highlight that MRI features are critical to successfully predict AD-related pathology years in advance which will improve participant selection for clinical trials, treatments, and intervention options.

Predicting Imminent Progression to Clinically Significant Memory Decline Using Volumetric MRI and FDG PET.

P1‐325: Predicting Progression to Mild Cognitive Impairment in Cognitively Unimpaired Individuals Using Neuroimaging Biomarkers

Improved Prediction of Imminent Progression to Clinically Significant Memory Decline Using Surface Multivariate Morphometry Statistics and Sparse Coding

DT‐01–06: Baseline FDG‐PET and Volumetric MRI Predicts Alzheimer's Disease Conversion from Mild Cognitive Impairment: an ADNI Study

Distinct Atrophy Pattern of Hippocampal Subfields in Patients with Progressive and Stable Mild Cognitive Impairment: A Longitudinal MRI Study

Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment

Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer’s Disease Progression

Enriching Amnestic Mild Cognitive Impairment Populations for Clinical Trials: Optimal Combination of Biomarkers to Predict Conversion to Dementia.

IC‐P‐089: Can Three Months MRI Volumetric Parameters Help the Prediction of Progression from MCI to Alzheimer's Disease? Results from the Addneuromed Study

IMPROVED PREDICTION OF PROGRESSION TO CLINICAL STAGES OF ALZHEIMER’S DISEASE USING MULTIVARIATE SURFACE MORPHOMETRY OF MRI BIOMARKERS AND PATCH-BASED SPARSE CODING

Prediction of Progressive Mild Cognitive Impairment by Multi-Modal Neuroimaging Biomarkers

Accuracy of Different Biomarkers to Predict Progression from Mild Cognitive Impairment to Probable Alzheimer's Dementia in Two Independent Clinical Series

[O1–12–02]: PROGRESSION FROM PRECLINICAL AD TO MCI OVER A DECADE: COGNITIVE AND BRAIN IMAGING TRAJECTORIES

Analysis of Regional MRI Volumes and Thicknesses As Predictors of Conversion from Mild Cognitive Impairment to Alzheimer's Disease

MRI Characterizes the Progressive Course of AD and Predicts Conversion to Alzheimer’s Dementia 24 Months Before Probable Diagnosis

Combined Neuroinflammation and Amyloid PET Markers in Predicting Disease Progression in Cognitively Impaired Subjects

Exploring the power of MRI and clinical measures in predicting Alzheimers disease neuropathology

Predicting progression from subjective cognitive decline to mild cognitive impairment or dementia based on brain atrophy patterns

MICROGLIAL ACTIVATION AND TAU BURDEN PREDICT COGNITIVE DECLINE IN ALZHEIMER’S DISEASE

A ‘Framingham-Like’ Algorithm for Predicting 4-Year Risk of Progression to Amnestic Mild Cognitive Impairment or Alzheimer’s Disease Using Multidomain Information

Multiple Early Biomarkers to Predict Cognitive Decline in Dementia-Free Older Adults